LEVERAGE LONG - ELI LILLY & CO | Real-time Borsa Italiana 06:29:22 2024-05-27 EDT | ||
| 54.47 EUR | -0.15% |
|
| Current month | +7.70% | ||
| 1 month | +43.10% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-05-27 | 54.47 | -0.15% |
| 24-05-24 | 54.55 | +0.28% |
| 24-05-23 | 54.4 | +2.99% |
| 24-05-22 | 52.82 | -0.94% |
| 24-05-21 | 53.32 | +12.73% |
Real-time Borsa Italiana
Last update May 27, 2024 at 06:29 am
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| SLLY5L | |
| ISIN | DE000SU2FTN1 |
| Date issued | 2023-11-24 |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 21.68 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 67.9 € |
|---|---|
| Lowest since issue | 14.05 € |
| Spread | 0.55 € |
| Spread % | 1.00% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
807.4
USD
Average target price
850.8
USD
Spread / Average Target
+5.37%
- Stock Market
- Certificates
- SLLY5L Certificat
